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Abstract
Background: Detection of autoantibodies giving nuclear rim pattern by immunofluorescence (anti-nuclear
envelope antibodies - ANEA) in sera from patients with primary biliary cirrhosis (PBC) is a useful tool for the
diagnosis and prognosis of the disease. Differences in the prevalence of ANEA in PBC sera so far reported have
been attributed to the methodology used for the detection as well as to ethnic/geographical variations. Therefore,
we evaluated the prevalence of ANEA in sera of Greek patients with PBC by using methods widely used by clinical
laboratories and a combination of techniques and materials.
Methods: We screened 103 sera by immunoblotting on nuclear envelopes and indirect immunofluorescence (IIF)
using cells and purified nuclei. Reactivities against specific autoantigens were assessed using purified proteins,
ELISA, immunoprecipitation and mass spectrometry.
Results: We found higher prevalence of ANEA when sera were assayed by IIF on purified nuclei or cultured cells
(50%) compared to Hep2 commercially available slides (15%). Anti-gp210 antibodies were identified in 22.3% and
33% of sera using ELISA for the C-terminal of gp210 or both ELISA and immunoprecipitation, respectively.
Immunoblotting on nuclear envelopes revealed that immunoreactivity for the 210 kDa zone is related to anti-
gp210 antibodies (p < 0.0001). Moreover, we found that sera had antibodies for lamins A (6.8%), B (1%) and C (1%)
and LBR (8.7%), whereas none at all had detectable anti-p62 antibodies.
Conclusions: The prevalence of ANEA or anti-gp210 antibodies is under-estimated in PBC sera which are analyzed
by conventional commercially available IIF or ELISA, respectively. Therefore, new substrates for IIF and ELISA should
be included by clinical laboratories in the analysis of ANEA in autoimmune sera.
Background
Nuclear envelope is a complex structure consisting of
outer and inner nuclear membranes, nuclear pore com-
plexes (NPCs) and the nuclear lamina [1]. The outer
nuclear membrane represents an extension of the endo-
plasmic reticulum, whereas the inner part constitutes a
specialized environment that accommodates a unique
set of proteins (LBR, emerin, LAP1s, and LAP2s). The
nuclear lamina is composed of A- and B-type lamins.
These proteins form a polymeric lining that supports
the inner nuclear membrane and imparts elasticity to
the nuclear envelope. NPCs provide the sole means for
regulated transport between the cytoplasm and the
nucleoplasm and are conserved in all eukaryotic cells,
from yeast to human. The mammalian NPCs are 125-
MDa complexes containing 30 distinct polypeptides,
called nucleoporins [2].
In a number of diseases, such as autoimmune liver and
systemic rheumatic pathologies, a correlation with auto-
antibodies against nuclear envelope (ANEA) was
reported [3]. Among them, primary billiary cirrhosis
(PBC) is one of those in which ANEA have been consid-
ered as pathognomonic element [4,5]. However, a signifi-
cant variation of their prevalence (between 10% and 48%)
has been reported, when indirect immunofluorescence
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could be attributed to differences on the processing of
IIF samples, namely substrates and reagents used for the
detection and on the evaluation of the results, especially
when antibodies of cytoplasmic specificities are present
in the same serum [3,4,11].
PBC sera may contain a number of autoantibodies
against specific constituents of the nuclear envelope.
Antibodies against proteins of the nuclear pore complex,
such as gp210, an integral glycoprotein of the nuclear
pore membrane, and p62, a nucleoporin of the central
channel, have been reported [10,12], being associated
with the activity and severity of PBC [13]. In addition, it
was recently suggested that anti-gp210 antibodies may be
related to the hepatic failure-type of the disease [14]. The
presence of anti-gp210 autoantibodies in PBC sera has
been reported for the first time in 1990 [15] and shortly
after, a 15-amino acid linear stretch within the carboxy-
terminal domain of the protein, has been shown to be
the predominant epitope [16]. Moreover, autoantibodies
against gp210 have been demonstrated to recognize at
least two different epitopes: one within the cytoplasmic
tail and another located within the large glycosylated
lumenal domain [17]. However, thereafter and until
today, anti-gp210 antibodies in sera of patients with PBC
from USA [18], Europe [9,19-22] and Asia [14,23,24]
were identified essentially by ELISA, using as an antigen
the carboxy-terminal domain of the protein. These stu-
dies have shown different prevalence (10.4%-44%) for
anti-gp210 autoantibodies, which have been essentially
attributed to geographical and/or ethnic variations.
Autoantibodies against p62 have been reported for the
first time in 1996 by two groups in Europe and Japan
[8,10]. Using immunoblotting, they have shown that
antibodies in PBC sera recognize a 62 kDa protein in a
nuclear pore complex-enriched preparation with a pre-
valence of 32% in PBC patients [10]. An immunoreactive
62 kDa band was shown with a similar frequency (31%),
after immunoblotting of PBC sera on a WGA-bound
fraction of rat liver nuclear envelopes [7]. Using recom-
binant autoantigens, PBC sera was found to react more
frequently with p62 (55%) than gp210 (10%) nucleoporin
[25] and that more than 50% of PBC sera precipitated
35S-radioactively labeled p62 recombinant rat or human
nucleoporin, while 40% recognized this recombinant
antigen by immunoblotting [26].
Antibodies against lamin B receptor (LBR), an integral
protein of the inner nuclear membrane, are specific for
PBC and when detected in sera, their positivity ranged
from 1% to 9% [7,9,15]. It has been also shown that
anti-LBR autoantibodies recognize intact or the N-term-
inal domain of human, rat and chicken LBR [15,27,28].
The aim of this study was to establish an IIF proce-
dure, which allows the efficient and easy detection of
ANEA and to determine the prevalence of different
ANEA autoantibody classes, specific for PBC. We report
that ANEA and more specifically anti-gp210 are present
with high frequency in PBC sera. Antibodies against
other components of the nuclear envelope, such as LBR
and lamins, are detected with low prevalence, whereas
anti-p62 antibodies are absent.
Methods
Patients and sera
Serum samples from one hundred and three (103)
patients (92 female and 11 male) with established PBC
were used. All patients were followed at the Department
of Gastroenterology, University Hospital of Heraklion,
Greece. PBC was diagnosed according to established
clinical, laboratory and histological findings [29] and
86% of sera contained anti-mitochondrial antibodies. In
addition, we analyzed by IIF sera from 10 healthy con-
trols, 25 individuals without autoimmune diseases regis-
tered with the university hospital, 5 patients with viral
hepatitis B, 5 patients with viral hepatitis C and 10
patients with alcoholic cirrhosis. All patients consented
to be included in the study which has been approved by
the Ethics and Scientific Committees of the University
Hospital of Heraklion.
Antibodies
Mouse monoclonal antibody p62 (BD Transduction
Laboratories, Becton Drive, Franklin Lakes, New Jersey,
USA) or mouse monoclonal antibody 414 which binds
to FXFG-containing nup358, nup214, nup153, p62 and
nup54 (Covance, Emeryville, California, USA) were used
for immunoprecipitation and immunoblotting experi-
ments. The characterization of affinity purified, rabbit
polyclonal anti-chicken LBR has been described pre-
viously [30].
Cell lines and culture
HeLa cells (cervical adenocarcinoma) were cultured in
Dulbecco’s MEM (Biochrom, Berlin, Germany), supple-
mented with 10% heat-inactivated fetal bovine serum,
penicillin and streptomycin. HepG2 cells (Human Hepa-
tocellular liver carcinoma cell line) were maintained in
DMEM/HAM’S F-12 (1:1) with N- Acetyl - L- Alanyl-
L- glutamine (Biochrom, Berlin, Germany) containing
10% FBS, penicillin, and streptomycin. Both cell lines
were obtained from the American Type Tissue Culture
Collection (Manassas, VA) and were grown at 37°C in a
humidified incubator with a 5% CO2 atmosphere.
Isolation of nuclei from rat liver and HepG2 cells
Rat liver nuclei were prepared as described by Blobel
and Potter [31]. To isolate nuclei from HepG2 cell cul-
tures, single cells were incubated in ice-cold hypotonic
Tsangaridou et al. BMC Gastroenterology 2010, 10:28
http://www.biomedcentral.com/1471-230X/10/28
Page 2 of 13buffer and then Dounce-homogenized as described [11].
Purity of nuclei was examined by indirect immunofluor-
escence and immunoblotting.
Immunostaining and Confocal Microscopy
Sera (dilution 1/80) were tested on HeLa and HepG2
cells grown on coverslips and isolated nuclei from rat
liver and HepG2 cells immobilized on coverslips using
alcian blue by indirect immunofluorescence (IIF) per-
formed as described previously [11]. Sera (dilution 1/80)
were also analyzed using commercially available Hep2
cells (Inova Diagnostics, San Diego, CA) following the
instructions of the supplier. In all cases, detection was
made by a supplied FITC-coupled anti-human IgG anti-
body, diluted and ready for use (Inova Diagnostics, San
Diego, CA) or FITC-coupled anti-human antibody IgM
(DAKO, Carpinteria, CA) at a dilution of 1/100. Fluores-
cence was routinely assayed in a Leica SP confocal micro-
scope (Leica microsystem Heidelberg GmbH, Germany)
Preparation of nuclear envelopes and proteins of the
nuclear envelope
Nuclear envelopes were prepared from isolated rat liver
nuclei following DNAse and RNAse digestion and
washes with high salt buffer and ice-cold distilled water
as previously reported [11].
Lamins A, C and lamin B were extracted from rat liver
nuclear envelopes (RNE) with 8 M urea and further pur-
ified by ion exchange chromatography (DE52, Whatman
International Ltd Maidstone, UK). The nucleoplasmic
amino-terminal domain of chicken LBR fused to glu-
tathione-S-transferase (GST) was expressed in BL21
(DE3) cells and purified from lysates according to stan-
dard procedures.
Immunoblotting
Purified proteins, RNE, or immunoprecipitated material
were electrophoresed on a 7.5% SDS polyacrylamide gel,
transferred on nitrocellulose membrane and immumo-
blotted as previously described [11]. PBC sera, anti-p62
and anti-LBR antibodies were used at 1/300, 1/1000 and
1/200 dilution, respectively. Autoantibodies were recog-
nized using anti-human Ig, IgG (GE Healthcare, Buckin-
ghamshire, UK), (1/10000) or IgM, (Southern Biotech,
Birmingham, Alabama, USA) (1/8000) secondary antibo-
dies; monoclonal or polyclonal antibodies were detected
using anti-mouse or anti-rabbit secondary antibodies, all
conjugated with HRP (GE Healthcare, Buckinghamshire,
UK) at a dilution of 1/10000 and detected using the
ECL system (Thermo Scientific, Rockford, USA).
Immunoprecipitation
Immunoprecipitation of nucleoporin p62 was accom-
plished using monoclonal antibodies and extracts from
RNE. Nuclear pore proteins were extracted from RNE
w i t hb u f f e rS 1( 1 0 %s u c r o s e ,4 0m MT r i s - H C lp H7 . 5 ,
3 0 0m MN a C l , ,1m ME G T A ,2m MM g C l 2,1m M
PMSF, protease inhibitors) containing 0.3% Empigen BB
(Fluka, St Louis MO, USA) [32]. Extract was first clari-
fied by centrifugation (15000 g for 15 min, at 4°C) and
then cleared from proteins which bound to sepharose
beads by incubating clarified supernatant for 1 hour, at
4°C with protein G-Sepharose beads (GE Healthcare,
Buckinghamshire, UK), already treated with 1% filtered
fish skin gelatine. Cleared extract was incubated with 4
μg of mouse monoclonal anti-p62 antibodies (BD Trans-
duction Laboratories, Becton Drive, Franklin Lakes, New
Jersey, USA) or mouse monoclonal antibodies 414 (Cov-
ance, Emeryville, California, USA), overnight at 4°C and
then with gelatine treated protein G-Sepharose beads,
for 1.5 hour at 4°C. The immune complexes were recov-
ered by centrifugation, washed 7 times with buffer S1
and solubilized in loading buffer by heating at 100°C.
For the immunoprecipitation of nuclear envelope anti-
gens, autoantibodies were either absorbed or covalently
coupled to protein G-Sepharose beads (GE Healthcare,
Buckinghamshire, UK). In both protocols RNE were
extracted with buffer S2 (2% Triton X-100, 20 mM Tris-
HCl pH 7.5, 300 mM NaCl, 10% sucrose, 1 mM EGTA,
2m MM g C l 2, 1 mM PMSF, protease inhibitors) for 1
hour on ice. Extract was clarified by centrifugation at
15000 g for 15 minutes at 4°C and mixed with an equal
amount of buffer without NaCl and Triton X-100.
Finally, extract was incubated with gelatine treated pro-
tein G-Sepharose beads, for 1 hour, at 4°C, in order to
be cleared from proteins which they bound to sepharose
beads.
In the first protocol, sera were incubated with extract
overnight at 4°C. The immune complexes were then
incubated with protein G-Sepharose beads for 1.5 hour
at 4°C, washed 7 times with buffer (1% Triton, 150 mM
NaCl, 20 mM Tris-HCl pH 7.5, 10% sucrose, 1 mM
EGTA, 2 mM MgCl2,1m MP M S F ,p r o t e a s ei n h i b i t o r s )
and eluted in loading buffer by heating at 100°C for
15 minutes.
Alternatively, autoantibodies were covalently coupled
to protein G-Sepharose beads essentially as previously
reported [33]. For this, sera were incubated with protein
G-Sepharose beads for 1 hour at 4°C, washed twice with
0.1 M sodium tetraborate, pH 9 and then incubated
twice with freshly prepared 20 mM DMP (Dimethyl
pimelimidate dihydrochloride, Sigma, St Louis MO,
USA) in 0.1 M sodium tetraborate, pH 9 for 30 minutes
at room temperature. Beads were washed two times
with ice-cold 50 mM glycine, pH 2.5 to remove
uncoupled autoantibodies, and then 7 times with PBS.
Beads bearing the covalently linked autoantibodies were
incubated with extract overnight at 4°C. The immune
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7 times with buffer (1% Triton, 150 mM NaCl, 20 mM
Tris-HCl pH 7.5, 10% sucrose, 1 mM EGTA, 2 mM
MgCl2,1m MP M S F ,p r o t e a s ei n h i b i t o r s ) .T h ee l u t i o n
of bound autoantigens was performed by adding to
beads an equal volume of loading buffer and heating at
70°C for 15 minutes.
Mass spectrometry
Stained protein bands were in-gel digested with trypsin.
The extracted peptides were analysed by mass spectro-
metry using an LCQ-Deca mass-spectrometer as pre-
viously described [34] while protein identification was
performed with TurboSEQUEST software.
Enzyme-linked immunosorbent assay
The antibody titers to gp210 were determined using
ELISA kit (Inova Diagnostics, San Diego, CA) according
to the manufacturer’s protocol and instructions.
Statistical analysis
Statistical analysis was performed with the SPSS V16
(SPSS, Chicago, IL) program. Comparison between
values was accomplished using the c
2 test.
Results
Routine histological slides do not detect ANEA
in all positive sera of PBC patients. Alternative
substrate-fixation methods
Commercial Hep2-based histology slides, coupled with
an anti-IgG-FITC conjugate are routinely used for the
detection of circulating autoantibodies. Using this set of
reagents, we were able to detect ANEA in 15% of sera.
Use of anti-IgM or both anti-IgG and anti-IgM second-
ary antibodies revealed 13% and 23% of sera positive for
ANEA, respectively (Figure 1). However, as we have
reported previously [11] the origin and fixation method
of cells, used as a substrate, may represent sources of
variation of ANEA detection, in patients’ sera. In this
respect, here we tested HeLa and HepG2 cell lines and
isolated nuclei from HepG2 cells and rat liver. The rea-
son for using purified nuclei as substrate for the analysis
of autoimmune sera was to eliminate staining from
autoantibodies directed against cytoplasmic autoantigens
and therefore to enhance sensitivity in the detection of
ANEA (Figure 2). We used nuclei isolated from HepG2
cells instead of HeLa cells because unlike nuclei pre-
parations from HeLa cells, those from HepG2 cells were
free of cytoplasmic contaminations (Figure 3). We also
analyzed sera using nuclei from rat liver because of their
high purity after isolation, the convenience of tissue
availability and the diversity of normal (no cancerous)
cell types that constitute the whole tissue (liver) instead
of a cell line. The latter would enhance identification of
cell-type specific proteins, because liver contains hepato-
cytes, Kupffer cells, sinusoidal epithelia, perisinusoidal
lipocytes, an endothelial vasculature, and muscle cells.
In Figure 2, we show characteristic patterns observed
with a number of patients’ sera, which, as will presented
below, contain autoantibodies against specific nuclear
envelope proteins (anti-gp210-s54, s16, s189-, or anti-
lamin A-s32-). The use of different substrates resulted in
Figure 1 Prevalence of ANEA. Histograms showing the percentage of PBC sera containing ANEA of different Ig class as determined by IIF on
Hep2 slides, HeLa cells, rat liver nuclei (RLN) and either substrate. “IgG Total” or “IgM Total” represent the sum of sera which had ANEA of both
IgG and IgM antibodies (IgG+IgM) and those with either IgG class alone or IgM class alone, respectively.
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tained low titer of ANEA and/or high titer of antibodies
directed against cytoplasmic autoantigens, isolated nuclei
revealed ANEA more efficiently and easily than whole
cells (Figure 2, panels s32, s16 and s189). Interestingly
enough, rat liver nuclei, in spite of the species difference,
recognize human ANEA with the same efficacy as human
liver (HepG2) nuclei. ANEA detection using purified
nuclei was specific, as no staining of the nuclear periphery
was shown when we used sera containing only cytoplasmic
autoantibodies (Figure 2, panel s201, and Figure 4). In
addition, we did not detect any fluorescence of the nuclear
periphery in both Hep2 commercial slides and purified
nuclei when sera from 10 healthy controls, 25 individuals
without autoimmune diseases registered with the univer-
sity hospital, 5 patients with viral hepatitis B, 5 patients
with viral hepatitis C and finally 10 patients with alcoholic
cirrhosis were analyzed by IIF (not shown).
Staining on different substrates has been further
repeated with an anti-IgM antiserum, to account for
Figure 2 Validation of substrates used in IIF for the detection of ANEA. Hep2 slides, HeLa and HepG2 cells fixed with formaldehyde either
4% (upper panel) or 1% (lower panel) and purified nuclei from HepG2 cells and rat liver were incubated with various PBC sera (s54, s32, s16,
s189 and s201) and secondary anti-human FITC-labeled IgG antibodies, as described in Materials and Methods.
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Figure 4 Purity of nuclear envelopes isolated from rat liver. (A) Reactivity of PBC sera (s) as detected by IIF on HeLa cells and nuclei isolated
from rat liver. Note the cytoplasmic pattern of fluorescence and the absence of staining on nuclei. The same PBC sera were tested (B) for anti-
mitochondrial autoantibodies by dot blotting (mitochondria profile blot, Alphadia Diagnostic Products, Wavre, Belgium) and (C) on nuclear
envelopes from rat liver by immunoblotting. Note for all sera the presence of anti-mitochondrial autoantibodies and the absence of reactivity on
nuclear envelopes.
Tsangaridou et al. BMC Gastroenterology 2010, 10:28
http://www.biomedcentral.com/1471-230X/10/28
Page 6 of 13isotype-specific ANEA in sera of PBC patients. Repre-
sentative images are presented in Figure 5. We show
that detection of IgG and/or IgM antibodies was
depending on the patient’s serum, as well as on the sub-
strate used and that isolated nuclei could reveal ANEA
more efficiently than whole cells (Figure 5, panel IgG
pos.*/IgM pos.).
The prevalence of ANEA as determined in the differ-
ent substrate/antiserum used varies within the different
combinations (Figure 1). Alternative substrates (HeLa
cells and isolated nuclei) identify a significantly higher
number of sera, positive for ANEA. No significant dif-
ference was observed in the prevalence determined
using either whole cells or isolated nuclei or when all
methods were pooled for positivity in the totality of 103
sera examined. Most sera (44%) had both IgG and IgM
antibodies, whereas we found low percentage (4%) of
sera containing only IgM antibodies.
In conclusion, these data indicate that substrates and
secondary reagents used in immunofluorescence assays
are determinant factors for the detection of ANEA. Pur-
ified nuclei and appropriately fixed cells are better sub-
strates than commercial Hep2-based histology slides and
should be used for the determination of ANEA by IIF
when their presence is suspected in patients’ sera.
Correlation of immunofluorescence and immunoblotting
in the detection of ANEA
In order to confirm our IIF findings, we have tested all
sera, by immunoblotting, using purified rat liver nuclear
envelopes as substrate. With the exception of sera posi-
tive for anti-mitochondrial autoantibodies (Figure 4), all
sera positive for ANEA by IIF were also positive by
immunoblotting. A variety of reactive protein bands
were revealed (Figure 6); most sera bound to proteins
with an approximate mass of 210 kDa (35, 34% of sera)
and/or 75-55 kDa (39, 37.9% of sera). In order to further
characterize the major antigens targeted by circulating
autoantibodies, we have analyzed them, using a variety
of methods.
Anti-gp210 autoantibodies prevail in ANEA-positive
cases of PBC
Anti-gp210 antibodies were most probable to be present
as it is known that these antibodies are PBC-specific. As
presented above, our PBC sera revealed autoantibodies
Figure 5 Detection of ANEA of IgG and IgM class by IIF. Commercially available slides with Hep2 cells (Hep2 cells), cultured HeLa cells (HeLa
cells) and purified nuclei from rat liver (R.L. nuclei) were incubated with various PBC sera and secondary anti-human FITC-labeled IgG and IgM
antibodies, as described in Materials and Methods.
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~210 kDa. Using a commercial ELISA kit for anti-gp210
antibody detection, we detected 43.4% of cases positivity,
in ANEA IIF-positive sera. However, from the 35 sera,
exhibiting autoantibodies against a protein substrate of
~210 kDa, only 23 were identified as anti-gp210 positive
with ELISA (Figure 7). This discrepancy could indicate
the existence of other, yet unidentified proteins with a
similar apparent molecular mass, serving as targets of
ANEA autoantibodies. Alternatively, it is also possible
that anti-gp210 antibodies are not detected by ELISA
because they are directed against epitopes other than
the C-terminal of gp210 or belong predominantly to
other classes than IgG.
To discriminate between these possibilities we per-
formed immunoprecipitation experiments using Triton
X-100 extracted material from purified rat liver nuclear
envelopes. Material precipitated by immunoprecipita-
tion-competent sera was further immunoblotted with
anti-gp210 antibodies (Figure 8Ia). Alternatively, for
those sera which were not suitable for immunoprecipita-
tion (i.e. s196 and s202), we used serum 54, which was
competent for immunoprecipitation and positive for
anti-gp210 by ELISA. Immunoprecipitates were then
immunoblotted with the different sera to be tested using
as detection reagents anti-human IgG and, when neces-
sary, IgM secondary antibodies (Figure 8Ib, c). We
found 8/35 additional sera (22.9%) containing anti-
gp210 IgG autoantibodies, not revealed by ELISA,
whereas 3/35 sera (8.6%) contained anti-gp210 autoanti-
bodies of IgM class alone (Figure 7). The identity of the
gp210 substrate was further confirmed by mass spectro-
metry of the protein immunoprecipitated with sera 16
and 54.
Concluding, our results indicate that 34 of PBC sera
(33%) contained anti-gp210 autoantibodies, while 11 of
these sera could not be detected by ELISA, necessitating
additional assays. Also, there is a statistically significant
direct correlation (p < 0.0001) between the 210 kDa
zone detected by immunoblotting (35 sera) and the
identification of gp210 (34 sera) in the PBC sera tested.
Prevalence of anti-p62, anti-LBR and anti-lamin
autoantibodies in PBC sera
The second major protein band identified in 38% of
PBC patients’ sera (39 sera), has an apparent molecular
mass of 55-75 kDa. Therefore, we investigated the pre-
valence of anti-p62, anti-LBR and anti-lamin autoantibo-
d i e sw h i c hh a v eb e e np r e v i o u s l yr e p o r t e dt oo c c u ri n
autoimmune sera [3].
T h ep r e s e n c eo fa n t i - p 6 2a u t oantibodies was studied
by immunoblotting on material immunoprecipitated
using specific monoclonal anti-p62 antibodies. As shown
in Figure 8IV, monoclonal anti-p62 antibodies (a-p62)
Figure 6 Detection of ANEA by immunoblotting. Apparent molecular mass of nuclear envelope proteins from rat liver which are recognized
by autoantibodies comprised in selected PBC sera.
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parations (RNE), on the material extracted (Ext.) and
immunoprecipitated with anti-p62 antibodies (IPp62).
Moreover, is shown that there was no detectable p62 in
the extract after immunoprecipitation (Depl.Ext.) indi-
cating that almost all of the extracted p62 was absorbed
by anti-p62 antibodies. However, none of the patients
sera, recognizing an autoantigen of similar molecular
mass (55-75 kd) could react with the isolated p62, sug-
gesting the absence of specific anti-p62 autoantibodies.
Representative data from selected sera (s6, s32 and
s188) are presented in Figure 8IV, where is shown an
immunoreactivity for proteins of approximately 60 kDa
in the nuclear envelope preparation (RNE) and the
extracted material before (Ext.) and after (Depl.Ext.)
immunodepletion but not for p62 nucleoporin (IPp62).
A similar method was used to investigate the presence
of anti-lamin and anti-LBR autoantibodies. They were
also detected by immunoblotting on the corresponding
purified proteins. Anti-lamin and/or anti-LBR autoanti-
bodies were present in 14 sera; specifically 4 contained
anti-lamin A, 1 anti-lamin B, 6 sera contained a low
titer anti-LBR antibody, 2 sera contained both anti-
lamin A and anti-LBR and finally 1 serum was positive
for anti-lamin A/C and anti-LBR antibodies (Figure 9).
Figure 8II shows characteristic immunoreactivities for
lamin B (s6), lamin A (s50) and both lamins A and C
(s211), whereas in Figure 8III are presented profiles
from sera without (s33, s201) and with high (s211, s21)
or low (s196) titer of anti-LBR autoantibodies. The exis-
tence of anti-lamin A autoantibodies was further con-
firmed by identifying lamin A with mass spectrometry
in the immunoprecipitated material using serum 16.
In conclusion, our data indicate the complete absence
of anti-p62 autoantibodies, while a small number of sera
contained antibodies targeting LBR or nuclear lamins.
Discussion
Standard immunofluorescence has traditionally a lower
sensitivity, as compared to immunoblotting or ELISA,
for the detection of autoantibodies; however, molecular-
based assays enable the detection of a limited number of
selected targets, neglecting others of potential equal or
even higher importance. A contribution of the present
study is the finding that immunofluorescence may be a
powerful technique for the detection of ANEA, which
are often sub-optimally detected when autoantibodies of
other reactivities are equally present in a specific serum
[3,4,11]. In fact, we report high prevalence of autoanti-
bodies against the nuclear periphery (in about half of
Figure 7 Prevalence of anti-gp210 autoantibodies. On the top the reactivity by immunoblotting of the 35 different sera (s) with a protein
zone of approximately 210 kDa is shown. The presence (+) or the absence (-) of autoantibodies against gp210 in these sera is assayed by ELISA
and immunoprecipitation followed by immunoblotting. For details see text and Figure 8.
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(cultured cells and purified nuclei) and antisera (IgG
and IgM). In contrast, these antibody classes are under-
estimated, when standard IIF procedure (commercially
available Hep2 cells and IgG antisera) was used for the
detection. Interestingly enough, we further report that
heterologous systems (rat liver nuclei/human sera) may
also reveal, with a high specificity, ANEA autoantibo-
dies, a technique which might be of potential clinical
value.
Previously published studies shows a discrepancy in
the results obtained by IIF and immunoblotting or
ELISA. For example, in PBC sera, it has been shown
that the prevalence of antibodies giving a rim-like mem-
branous fluorescence (10%) by IIF on Hep2 cells was
lower than the prevalence of antibodies assayed by
ELISA against gp210 (16%), which represent one among
other autoantigens of the nuclear envelope. Moreover,
for specific sera which were negative for ANEA by IIF,
antibodies against gp210 or LBR have been detected
Figure 8 Identification of specific ANEA by biochemical approaches. (I) Identification of anti-gp210 autoantibodies. Immunoprecipitation (IP)
of gp210 and immunoblotting (Blot) using IgG (IgG) and IgM (IgM) secondary antibodies. (II) Identification of autoantibodies directed against
lamins A/C (LmA/C) and B (LmB) by immunoblotting (Blot) using purified proteins (SDS-PAGE). (III) Identification of anti-LBR autoantibodies by
immunoblotting (Blot) using purified recombinant LBR (SDS-PAGE). “d.p.” denotes characteristic proteolytic products of LBR that are produced
after expression in bacteria. Sera negative (s33, s201) and highly (s211, s21) or moderately (s196) positive for LBR are shown. (IV) Identification of
anti-p62 autoantibodies.
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antibodies, against at least one of the two major autoan-
tigens at about 200 and 60 kDa, were detected by
immunoblotting on purified human NPCs in as many as
22% of the ANA-negative by IIF PBC patients [13]. Our
data indicate that an accurate detection of ANEA by IIF
can be accomplished if appropriate substrates are used.
Cytoplasmic staining, which is a major handicap for the
detection of the peripheral nuclear staining very often
shown in PBC sera, was considerably decreased or even
eliminated when appropriately fixed cells or purified
nuclei were used. Sera tested under such conditions
showed high prevalence of ANEA by IIF. Of importance,
all sera which were positive for anti-gp210 and anti-LBR
autoantibodies showed also a peripheral nuclear staining
by IIF, indicating that ANEA specific for PBC, are effi-
ciently detected using our experimental protocol.
Another important finding was the identification of
undetectable by conventional ELISA, anti-gp210 autoan-
tibodies in more than 10% of PBC sera, representing
21% of sera with ANEA and 32% of anti-gp210 positive
sera. Three of 11 sera contained anti-gp210 of only IgM
class, whereas anti-gp210 autoantibodies in the last 8
sera did not reacted with the C-terminal epitope using
an ELISA commercial kit which is widely used in clini-
cal laboratories. Considering the importance of anti-
gp210 antibodies in diagnosis and prognosis of PBC, our
results strongly suggest that additional ELISA kits
should be developed including the N-terminal epitope
as substrate and various secondary reagents for the
identification of anti-gp210 autoantibodies of all specifi-
cities and Ig class.
Finally, we tried to identify the 60-70 kDa protein
zones recognized by almost 40% (39 out of 103 sera) of
our sera after immunoblotting on purified rat nuclear
envelopes. We identified autoantibodies for LBR or
lamins A, B and C, in 14 (36%) of those sera, whereas
we have not detected anti-p62 autoantibodies in our
PBC sera by immunoprecipitation, although p62 was
effectively recognized in the material extracted from rat
nuclear envelopes and precipitated using monoclonal
anti-p62 antibodies. Moreover, the immunoreactivity of
sera with a 60-70 kDa band in nuclear envelope extracts
before and after immunoprecipitation clearly indicated
that autoantibodies reacting with the 60-70 kDa proteins
are not directed against p62 but reacted probably with
degradation products of autoantigens of higher M.W.
(20 of 25 sera had autoantibodies for gp210) or proteins
of the nuclear envelope not yet reported as autoantigens.
T h eo n l yp o s s i b l ee x p l a n a t i o nf o rt h el a c ko fd e t e c t i o n
of anti-p62 autoantibodies could be their very low titer.
This possibility is supported by the recent identification
Figure 9 Prevalence of autoantibodies for lamins and LBR. On the top the reactivity by immunoblotting of the 39 different sera (s) with a
protein zone of molecular mass between 55 and 75 kDa is shown. The presence (+) or the absence (-) of autoantibodies against lamins A, B, C
and LBR in these sera is assayed by immunoblotting using purified proteins. “+l” denotes low titer for anti-LBR antibodies.
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Page 11 of 13of autoantibodies against p62 using recombinant rat or
human protein in 50% of PBC sera by immunoprecipita-
tion of
35S-radioactively labeled p62 and in 40% by
immunoblotting [26]. We believe that more studies are
needed to confirm the presence and determine the pre-
valence of anti-p62 antibodies in PBC sera.
Conclusions
Results of the present study indicate high prevalence of
autoantibodies giving rim/peripheral fluorescence in
PBC sera when tested by IIF using multiple secondary
reagents and adequate substrates for the analysis. We
confirm that among many potential ANEA, anti-gp210
antibodies are very specific for PBC, although their sen-
sitivity in PBC sera seems to be underestimated in pre-
vious studies. Giving the importance of ANEA and
particularly anti-gp210 antibodies in diagnosis and prog-
nosis of PBC, we suggest that modifications emerged by
our study, concerning the screening of sera by IIF and
the identification of gp210 antibodies, should be
included for the identification of ANEA in future
studies.
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